Optimizing Idiopathic Pulmonary Fibrosis Management
US Pharm. 2025;50(7):HS17-HS22. ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is the most common form of pulmonary fibrosis, affecting 140,000 individuals in the United States. It primarily impacts older adults, with a median survival of 4 to 5 years …